Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SFRP1 | Q8N474 | 11/20 | 0.52 |
| ▸ | WNT3 | P56703 | 5/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | BRD2 | P25440 | 3/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619410 | 0.91 | SFRP1 (0.57) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL6102553 | 0.89 | BRD4 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL4637314 | 0.89 | BRD4 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL4619287 | 0.89 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL4618174 | 0.89 | SFRP1 (0.55) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL4618272 | 0.88 | BRD4 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL4615963 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2SFRP1WNT3BRD4 | |
| SCHEMBL6101888 | 0.87 | SFRP1 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL6101893 | 0.86 | HTT (0.44) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 | |
| SCHEMBL4616495 | 0.86 | KMT2A (0.51) | ALDH1A1SMN1; SMN2L3MBTL1SFRP1WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ALDH1A1 1865/4885SMN1; SMN2 2404/4885L3MBTL1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.